Synonym
DA-3003-2; NSC 663285; NSC663285; NSC-663285;
IUPAC/Chemical Name
7-chloro-6-[[2-(4-morpholinyl)ethyl]amino]-5,8-quinolinedione
InChi Key
LGTBDMBBPVNDSZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H16ClN3O3/c16-11-13(18-4-5-19-6-8-22-9-7-19)14(20)10-2-1-3-17-12(10)15(11)21/h1-3,18H,4-9H2
SMILES Code
O=C(C(NCCN1CCOCC1)=C2Cl)C3=C(N=CC=C3)C2=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.
In vitro activity:
The antiproliferative efficacy of Cdc25 phosphatase inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2) was investigated in the PC-3 asynchronous human prostate cancer cell line using a cell-based assay. The time course changes in cell cycle distribution and the modulation of cell cycle regulators after DA 3003-2 administration were analyzed using the MTT assay. It was found that the relative IC(50) of DA 3003-2 was 2-fold lower as compared with its congener (2-mercaptoethanol)-3methyl-1, 4-naphthoquinone (NSC 672121). Asynchronous PC-3 cells accumulated in the G2/M phase at 24 h after treatment with 10 μM DA 3003-2 or 20 μM NSC 672121, which represent IC(70) concentrations. Treatment of cells with DA 3003-2 caused hyperphosphorylation of Cdc2 tyr(15) in cyclin B(1) and cyclin A complexes. DA 3003-2 did not downregulate the protein expression levels of Cdc25s, cyclins and cyclin-dependent kinases (Cdks). To conclude, after DA 3003-2 administration asynchronous PC-3 cells accumulated in the G2/M phase, with hyperphosphorylation of the G2/M cyclin-Cdk complex.
Reference: Exp Ther Med. 2010 Jul;1(4):647-650. https://pubmed.ncbi.nlm.nih.gov/22993588/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
30.0 |
93.24 |
| DMF |
20.0 |
62.16 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
321.76
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp Ther Med. 2010 Jul;1(4):647-650. doi: 10.3892/etm_00000101. Epub 2010 Jul 1. PMID: 22993588; PMCID: PMC3445938.
In vitro protocol:
1. Nemoto K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp Ther Med. 2010 Jul;1(4):647-650. doi: 10.3892/etm_00000101. Epub 2010 Jul 1. PMID: 22993588; PMCID: PMC3445938.
1. Lazo, J.S., Aslan, D.C., Southwick, E.C., et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. Journal of Medicinal Chemistry 44, 4042-4049 (2001).
2. Lavecchia, A., Cosconati, S., Limongelli, V., et al. Modeling of Cdc25B dual specifity protein phosphatase inhibitors: Docking of ligands and enzymatic inhibition mechanism. ChemMedChem 1(5), 540-550 (2006).
3. Nemoto, K. G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp.Ther.Med. 1(4), 647-650 (2010).
